Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

HIMS boasts high gross margins (~80%) with no R&D risk, capitalizing on the shift away from traditional pharmacies to ...

Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...

Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...

Hims & Hers Health Inc. ($HIMS) rallied nearly 9% in pre-market trading on Tuesday, following the company’s third-quarter ...

Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter ...

Hims & Hers currently offers compounded GLP-1 weight-loss injections at $199 per month and weight management oral medication ...

Hims&Hers Health (NYSE:HIMS) reported third-quarter earnings that surpassed analyst expectations and raised its full-year guidance, driven by strong subscriber growth and improving profitability.

Hims & Hers is taking a more serious approach to its latest campaign. The telehealth company, which is best known for its ...

Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...

Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.